Fig. 2From: The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studiesChange in MBDA score by EULAR response category at 6 months. Individual patient values of ∆MBDA score from baseline to 6 months are shown as dots, grouped by EULAR response category at 6 months (EULAR non-, moderate, good response). Dark lines represent median values. Whiskers represent interquartile ranges (25th–75th). ∆: changeBack to article page